

Resource Summary Report

Generated by [dkNET](#) on Aug 16, 2026

Brilliant Violet 605(TM) anti-human CD137 (4-1BB)

RRID:AB_2565997

Type: Antibody

Proper Citation

BioLegend Cat# 309822, RRID:AB_2565997

Antibody Information

URL: http://antibodyregistry.org/AB_2565997

Proper Citation: BioLegend Cat# 309822, RRID:AB_2565997

Target Antigen: CD137

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: FC

Antibody Name: Brilliant Violet 605(TM) anti-human CD137 (4-1BB)

Description: This monoclonal targets CD137

Target Organism: human

Clone ID: Clone 4B4-1

Antibody ID: AB_2565997

Vendor: BioLegend

Catalog Number: 309822

Alternative Catalog Numbers: 309821

Record Creation Time: 20250819T230822+0000

Record Last Update: 20250820T042438+0000

Ratings and Alerts

No rating or validation information has been found for Brilliant Violet 605(TM) anti-human CD137 (4-1BB).

No alerts have been found for Brilliant Violet 605(TM) anti-human CD137 (4-1BB).

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 5 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Franciosa G, et al. (2026) The proteomics and phosphoproteomics landscape of melanoma under T cell attack. Cell reports. Medicine, 7(6), 102829.

Vandoren R, et al. (2026) AIRRWAS integrates TCR-microbiome data to reveal how the gut microbiome shapes the circulating and mucosal T cell repertoire. Cell reports, 45(6), 117479.

Saggau C, et al. (2024) Autoantigen-specific CD4+ T??cells acquire an exhausted phenotype and persist in human antigen-specific autoimmune diseases. Immunity, 57(10), 2416.

Kilgour MK, et al. (2022) Principles of reproducible metabolite profiling of enriched lymphocytes in tumors and ascites from human ovarian cancer. Nature protocols, 17(11), 2668.

Montel-Hagen A, et al. (2019) Organoid-Induced Differentiation of Conventional T Cells from Human Pluripotent Stem Cells. Cell stem cell, 24(3), 376.